Epidemiological data and screening criteria of the metabolic syndrome

被引:7
作者
Boulogne, A [1 ]
Vantyghem, MC [1 ]
机构
[1] CHU Lille, Clin Endocrinol, Serv Endocrinol & Metab, Lille, France
来源
PRESSE MEDICALE | 2004年 / 33卷 / 10期
关键词
D O I
10.1016/S0755-4982(04)98711-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three definitions The metabolic or X syndrome is defined by an association of metabolic anomalies leading to an increased risk of cardiovascular complications. Today, there are at least 3 definitions of X syndrome: those of WHO, EGIR and NCEP. To varying degrees they associate increased abdominal fat, hypertension, glucose tolerance abnormality (ranging from hyperinsulinism to diabetes), and hypertriglyceridemia with low HDL cholesterol. From an epidemiological point of view The prevalence of metabolic syndrome depends on the definition used and varies with the country or ethnic group considered. About 25% of the US and 10% of the French adult populations are concerned. The risk of complications According to clinical trials, people with metabolic syndrome have a 2 to 4-fold increase in risk for coronary heart disease. Some of them have a particularly high risk (association of most features of the syndrome, association of an increased waist circumference and hypertriglyceridemia, presence of biological markers such as elevated C-reactive protein or microalbuminuria). Metabolic syndrome is also associated with a 4-fold increase in risk for developing diabetes.
引用
收藏
页码:662 / 665
页数:4
相关论文
共 15 条
  • [1] ALBERTI KG, 1999, NCS992 WHO
  • [2] The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome.: The French DESIR study
    Balkau, B
    Vernay, M
    Mhamdi, L
    Novak, M
    Arondel, D
    Vol, S
    Tichet, J
    Eschwège, E
    [J]. DIABETES & METABOLISM, 2003, 29 (05) : 526 - 532
  • [3] Balkau B, 1999, DIABETIC MED, V16, P442
  • [4] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [5] Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey
    Ford, ES
    Giles, WH
    Dietz, WH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03): : 356 - 359
  • [6] A comparison of the prevalence of the metabolic syndrome using two proposed definitions
    Ford, ES
    Giles, WH
    [J]. DIABETES CARE, 2003, 26 (03) : 575 - 581
  • [7] Medical progress - Acquired and inherited lipodystrophies
    Garg, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) : 1220 - 1234
  • [8] GOMILA S, 2003, MED NUTR, V39, P89
  • [9] Cardiovascular morbidity and mortality associated with the metabolic syndrome
    Isomaa, B
    Almgren, P
    Tuomi, T
    Forsén, B
    Lahti, K
    Nissén, M
    Taskinen, MR
    Groop, L
    [J]. DIABETES CARE, 2001, 24 (04) : 683 - 689
  • [10] Kylin E, 1923, Zentralblatt fuer Inn Medizin, V44, P105, DOI DOI 10.1002/(SICI)1096-9136(199807)15:7<539::